Free shipping on all orders over $ 500

SKLB1002

Cat. No. M3013
SKLB1002 Structure
Size Price Availability Quantity
10mg USD 140  USD140 In stock
50mg USD 440  USD440 In stock
100mg USD 680  USD680 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.

Protocol (for reference only)
Cell Experiment
Cell lines HUVECs, L-02, B16-F10, HepG2, and SW620 cells.
Preparation method Cell proliferation Using MTT assay to measure cell proliferation . Various cells including HUVECs, L-02, B16-F10, HepG2, and SW620 are treated with indicated concentrations of SKLB1002 for 24 hours. Vandetanib and sunitinib serve as positive controls. Each assay is replicated 3 times.
Concentrations ~40 μM
Incubation time 24 hours
Animal Experiment
Animal models Mice bearing SW620 or HepG2 tumors
Formulation 35% (v/v) polyethylene glycol solution containing 5% (v/v) DMSO
Dosages ~100 mg/kg daily
Administration i.p.
Chemical Information
Molecular Weight 320.39
Formula C13H12N4O2S2
CAS Number 1225451-84-2
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Qiu-Yang Zhang, et al. SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo

[2] Heng-Xiu Yan, et al. A new selective vascular endothelial growth factor receptor 2 inhibitor ablates disease in a mouse model of psoriasis

[3] Wen Nie, et al. Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26

[4] G Shen, et al. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy

[5] Shuang Zhang, et al. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo

Related VEGFR/PDGFR Products
Isolinderalactone

Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of VEGFR2 activation in endothelial cells. Isolinderalactone suppressed the expression of B-cell lymphoma 2 (BCL-2), as well as of survivin and X-linked inhibitor of apoptosis protein (XIAP).

Oglufanide

Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus.

KLTWQELYQLKYKGI

KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF.

Protein LMWP

Protein LMWP is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity.

CBO-P11

CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis.

  Catalog
Abmole Inhibitor Catalog




Keywords: SKLB1002 supplier, VEGFR/PDGFR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.